|
Introduction
Antidepressants have varying potentials to cause
discontinuation syndromes.
Symptoms begin within a few days of stopping or reducing the dosage of the drug
and are usually mild and short-lived. However, in some patients,
antidepressant
discontinuation symptoms can produce significant morbidity, be incorrectly
attributed to other causes, and lead to subsequent lack of compliance with
antidepressant therapy.
The best approach to the problem is prevention, which
involves educating patients and healthcare professionals about discontinuation
symptoms and ensuring that antidepressants are tapered before they are stopped.
When symptoms do occur, reassurance is usually sufficient; in some patients,
however, there may be a need for symptomatic treatment, temporary reinstatement
of the antidepressant (followed by careful tapering), or a switch to
fluoxetine
(which has a low potential for discontinuation symptoms). More research into
this common and clinically relevant syndrome is required so that evidence-based
recommendations can be developed.
All Types of Antidepressants Are Implicated
So far, at least 21 different antidepressants have been reported to cause
discontinuation symptoms (table 1). All major classes of antidepressants have
been implicated.[1]
Many Different Syndromes Exist
Discontinuation syndromes vary considerably with respect to symptom type,
grouping and severity. General features associated with discontinuation
syndromes involving different classes of antidepressants are as follows:
- in patients stopping selective serotonin reuptake inhibitors (SSRIs),
the most common discontinuation syndrome involves 6 main symptom groups
(table 2). Both physical and psychological symptoms may be experienced; the
most commonly reported symptoms are dizziness, nausea, lethargy and headache[2]
- as with SSRIs, tricyclic antidepressant (TCA)-associated discontinuation
syndromes also include both physical and psychological symptoms but are much
less likely to be associated with sensory abnormalities and problems with
equilibrium (table 2). Hypomania, akathisia, parkinsonism, cardiac
arrhythmias, panic attacks and delirium have been reported on rare occasions
in patients discontinuing TCAs[1]
- stoppage of venlafaxine can result in an SSRI-like discontinuation
syndrome[1]
- monoamine oxidase inhibitor (MAOI) discontinuation syndromes,
particularly those involving tranylcypromine, can result in psychotic
confusion, worsening of depressive symptoms, hypomania and generalised
seizures.[1]
Key Clinical Features Suggest the Diagnosis
Common clinical features of antidepressant discontinuation syndromes include
the following:
- antecedent antidepressant discontinuation or (less commonly) dosage
reduction
- appropriate onset, i.e. usually within a few days of discontinuing or
reducing the dose of an antidepressant
- adequate duration of treatment. Antidepressant discontinuation symptoms
are rare in patients who have been treated for less than 5 weeks
- short duration (between 1 day and 3 weeks) if left untreated
- rapid reversibility (within 24 hours) on recommencement of the withdrawn
drug.[1]
It is important to note, however, that while most antidepressant
discontinuation reactions are mild and transient, others may persist for up to 3
months and/or be associated with substantial morbidity.[1]
Discontinuation Symptoms Common...
Discontinuation symptom rates in patients taking older antidepressants can be
high, as evidenced by reports of 100% with imipramine, 80% with amitriptyline,
33% with clomipramine and 32% with phenelzine.[1] Abrupt
discontinuation of treatment with newer agents such as sertraline,[3]
paroxetine,[3,4] and venlafaxine[5] also results in
spontaneously reported discontinuation symptoms in at least 1 out of 3 patients.
Even higher rates have been documented when patients are specifically asked
about symptoms, with one study finding evidence of discontinuation syndromes in
2 out of 3 patients treated with paroxetine and sertraline.[6]
...Except in Patients Taking Fluoxetine
Presumably because of the long half-lives of the parent drug (2 to 4 days)
and its active metabolite norfluoxetine (7 to 15 days), fluoxetine appears to be
much less likely to be associated with discontinuation symptoms than SSRIs such
as paroxetine and sertraline.[1,7] When spontaneous adverse drug
reaction reports in the UK (up to March 1993) were analysed, the rate of
discontinuation reactions per 1000 prescriptions was 100 times lower with
fluoxetine than with paroxetine (0.002 vs 0.3 per 1000, respectively) [see fig.
1].[8] Furthermore, in a double-blind placebo-controlled 'treatment
interruption' study, discontinuation of fluoxetine for 5 to 8 days was found to
produce fewer adverse events than discontinuation of sertraline or paroxetine
for a similar length of time (p </= 0.001).[6]
Good History Makes Diagnosis Easier...
Unexpected physical or psychological symptoms in a patient who has recently
stopped taking an antidepressant point to an antidepressant discontinuation
syndrome. The diagnosis also becomes clearer when direct questioning reveals
noncompliance with therapy in patients currently on an antidepressant
prescription.[1]
Continue page 2
top .
pages
1
2
3 .
send to friend .
depression site map
Reviewed: 12/2001
|
|